Business
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
SAN DIEGO, April 27, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026.
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3600,"height":1320,"url":"https://media.zenfs.com/en/business-wire.com/0e9d7d2d2bd87e9c5a06a901f69956ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AsKN42hzcO1ZBvrZ7otgsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1Mg--/https://media.zenfs.com/en/business-wire.com/0e9d7d2d2bd87e9c5a06a901f69956ff","width":960,"height":352},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Bx6x7vnZDnqMg_2yKOJF0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04ODA-/https://media.zenfs.com/en/business-wire.com/0e9d7d2d2bd87e9c5a06a901f69956ff","width":1200,"height":440}},"lazy":false},{"type":"text","content":"SAN DIEGO, April 27, 2026--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026.","length":484,"tagName":"p"},{"type":"text","content":"Arcturus Therapeutics First Quarter 2026 Earnings Conference Call","length":65,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Thursday, May 7, 2026, at 4:30 p.m. ET","length":38,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Domestic: 1-800-579-2543","length":24,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"International: 1-785-424-1789","length":29,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Conference ID: ARCTURUS","length":23,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Webcast: Link","length":13,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":127,"olType":false},{"type":"text","content":"About Arcturus","length":14,"tagName":"p"},{"type":"text","content":"Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology ...